How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,727 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Clinical Criteria for the Evaluation of Caries Lesions Around Restorations in Primary Teeth (CARDEC-03)

and then, will be monitored for two years. Reassessments will be performed by a blind examiner in relation to the child's allocation group, and the occurrence of outcomes will be assessed according to predefined criteria described for evaluation of restorations performed in the context of atraumatic restorative treatment. The primary outcome will be the need for restorative intervention during the follow-up of the restorations evaluated by the different criteria. This outcome is composed of several components (...) of the children according to the diagnosis criteria Outcome Measures Go to Primary Outcome Measures : Operative treatment needs of the evaluated restorations (success of restoration) [ Time Frame: 24 months ] The necessity to repair the evaluated restorations during the follow-up examinations will be assessed by the Roeleveld et al. (1996) criteria (scores 11, 12, 13 and 30) or Frencken et al. (1996) criteria (scores 2 and 3). The criteria are described below: Roeleveld et al. (1996): Score 11 - Restoration

2018 Clinical Trials

82. ACC/AAP/AHA/ASE/HRS/SCAI/SCCT/SCMR/SOPE 2014 Appropriate Use Criteria for Initial Transthoracic Echocardiography in Outpatient Pediatric Cardiology

, FACC, FAAP, FASE Rating Panel Robert M. Campbell, MD, FACC, FAHA, FAAP, FHRS, Chair* PamelaS.Douglas,MD,MACC,FAHA,FASE, Moderator* Louis I. Bezold, MD, FACC, FAAP, FASEy William B. Blanchard, MD, FACC, FAHA, FAAP* Jeffrey R. Boris, MD, FACC* Bryan Cannon, MDz Gregory J. Ensing, MD, FACC, FASEx Craig E. Fleishman, MD, FACC, FASEjj Mark A. Fogel, MD, FACC, FAHA, FAAP{ B. Kelly Han, MD, FACC# Shabnam Jain, MD, MPH, FAAP* Mark B. Lewin, MDjj Richard Lockwood, MD** G. Paul Matherne, MD, MBA, FACC (...) COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 http://dx.doi.org/10.1016/j.jacc.2014.08.003 PUBLISHED BY ELSEVIER INC. Downloaded From: http://content.onlinejacc.org/ on 09/29/2014Appropriate Use Criteria Task Force Manesh R. Patel, MD, FACC, Chair Christopher M. Kramer, MD, FACC, FAHA, Co-Chair Steven R. Bailey, MD, FACC, FAHA, FSCAI Alan S. Brown, MD, FACC John U. Doherty, MD, FACC, FAHA Pamela S. Douglas, MD, MACC, FAHA, FASE Robert C. Hendel, MD, FACC, FAHA, FASNC Bruce D. Lindsay, MD

2014 Society for Cardiovascular Angiography and Interventions

83. Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria?A 10-Year Update

Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria?A 10-Year Update STANDARDS OF PRACTICE Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update Muneeb Ahmed, MD, Luigi Solbiati, MD, Christopher L. Brace, PhD, David J. Breen, MD, Matthew R. Callstrom, MD, PhD, J. William Charboneau, MD, Min-Hua Chen, MD, Byung Ihn Choi, MD, Thierry de Baère, MD, Gerald D. Dodd, III, MD, Damian E. Dupuy, MD, Debra A. Gervais, MD, David (...) (C.T.S., S.B.S.); Department of Radi- ology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (M.C.S.); Department of Hepatology, Yokokura Hospital, Miyama, Japan (M. T.); Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Johann Wolfgang Goethe-University, Frankfurt, Germany (T.J.V.); Radiology and Imaging Science, National Institutes of Health, Bethesda, Maryland (B.J.W.); and Department of Radiology, Image-Guided Therapy and Interventional

2014 Society of Interventional Radiology

84. Modification of diagnostic criteria for essential thrombocythaemia

Access Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia E-mail address: Department of Haematology, Guy's and St Thomas, Hospitals' NHS Foundation Trust, London, UK Department of Haematology, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK Welcome Trust Sanger Institute, Cambridge, UK Department of Haematology, St James' Hospital, Dublin, UK Beatson Oncology Centre, Glasgow, UK Univeristy of Cambridge (...) into low and intermediate and vice versa . The management of intermediate risk ET is uncertain and has only been tested in the PT‐1 intermediate risk study, which has not yet been reported and uses a different definition of intermediate risk. Conflict of interest The authors have no conflicts of interest to disclose. All authors have contributed equally to this document. References Barbui, T. , Finazzi, G. , Carobbio, A. , Thiele, J. , Passamonti, F. , Rumi, E. , Ruggeri, M. , Rodeghiero, F. , Randi

2014 British Committee for Standards in Haematology

85. Criteria for the appropriate use of positron emission tomography with FDG (FDG-PET) in head and neck cancer

of the quality of this assessment has been made for the HTA database. Citation Ballini L, Vignatelli L, Maltoni S. Criteria for the appropriate use of positron emission tomography with FDG (FDG-PET) in head and neck cancer. Bologna: Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR). ORIentamenti 7. 2012 Authors' conclusions Aim: The criteria reported in this document are to be intended as guidance for programs of clinical governance aimed at: supporting clinicians on the use of FDG-PET (...) in oncology. For each indication a systematic review was performed. The GRADE approach was applied to assess the quality of included studies, the level of confidence in the overall evidence for each outcome of interest. The GRADE approach for diagnostic recommendations was also used to elicit judgement from the panel members on benefit and harms trade-off for patient-important outcomes. The RAND method was used to vote and reach an agreement on the appropriateness criteria. Results: The panel examined

2012 Health Technology Assessment (HTA) Database.

86. Appropriate Use of Cardiovascular Technology: 2013 ACCF Appropriate Use Criteria Methodology Update

Appropriate Use of Cardiovascular Technology: 2013 ACCF Appropriate Use Criteria Methodology Update APPROPRIATE USE CRITERIA Appropriate Use of Cardiovascular Technology 2013 ACCF Appropriate Use Criteria Methodology Update A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force Appropriate Use Criteria Task Force Robert C. Hendel, MD, FACC, FAHA, FASNC Manesh R. Patel, MD, FACC Joseph M. Allen, MA James K. Min, MD, FACC Leslee J. Shaw, PHD, FACC, FASNC (...) - mendationsregardingmultipleprocedures.Abriefsummaryof studies examining the AUC process and their evaluation and implementation to date is also provided. De?ning Appropriate Use In the ?rst series of AUC documents, there was strict adherence to the terms of appropriateness established by RAND methodology, including the title, “appropriateness criteria” (6–8). More recent documents have adopted the term “Appropriate Use Criteria.” This change re?ects the more active function of the AUC in promoting evidence- based, effective use of cardiovascular

2013 Society for Cardiovascular Angiography and Interventions

87. AIUM Practice Parameter for the Performance of an Ultrasound Examination in the Practice of Urology

. The parameters reflect what the AIUM considers the minimum criteria for a complete examination in each area but are not intended to establish a legal standard of care. AIUM-accredited practices are expected to generally follow the parameters with recognition that deviations from these parameters will be needed in some cases, depending on patient needs and available equipment. Practices are encouraged to go beyond the parameters to provide additional service and information as needed. 14750 Sweitzer Ln, Suite (...) . Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am 2006; 44:689–710, viii. 21. Zalesky M, Urban M, Smerhovsky Z, Zachoval R, Lukes M, Heracek J. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer . Int J Urol 2008; 15:68–75. C. Scrotal 1. Indications Indications for a scrotal ultrasound examination include but are not limited to: • Evaluation

2011 American Institute of Ultrasound in Medicine

88. Vitamin E infused Polyethylene Liners, Regular Polyethylene Liners, Cross-Linked Polyethylene Liners for Knee Articular Surfacing in Adults : A Review of Clinical Effectiveness and Cost Effectiveness

Articular Resurfacing 2 oxidation. 7 It is believed vitamin E may reduce the rate of revision surgery (or failure). 7 In addition, there are claims vitamin E may improve tensile strength while preventing polyethylene degeneration by oxidation. 6 The purpose of the current review is to examine the comparative clinical effectiveness and cost- effectiveness of vitamin E infused polyethylene liners, cross-linked polyethylene liners and conventional polyethylene liners for knee articular resurfacing (...) between January 1, 2007 and October 25, 2012. Selection Criteria and Methods One reviewer screened the titles and abstracts of the retrieved publications and evaluated the full-text publications for final article selection (Table 1). Vitamin E Infused, Conventional, and Cross-Linked Polyethylene Liners for Knee Articular Resurfacing 3 Table 1: Selection Criteria Population Adults undergoing knee articular resurfacing Intervention THREE COMPARISONS 1. Vitamin E infused polyethylene liners versus cross

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

89. Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

90. Vertigo control in M‚niŠre's disease following transmyringeal ventilation tube insertion: a systematic review on the current state of the evidence

Vertigo control in M‚niŠre's disease following transmyringeal ventilation tube insertion: a systematic review on the current state of the evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria

2019 PROSPERO

91. Use of M-health as a strategy to improve the cardiovascular performance of cardiac patients belonging to the cardiovascular rehabilitation program

Use of M-health as a strategy to improve the cardiovascular performance of cardiac patients belonging to the cardiovascular rehabilitation program Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria

2019 PROSPERO

92. Effectiveness of M-health applications on hypertension management: a systematic review and meta-analysis of randomized controlled trials

Effectiveness of M-health applications on hypertension management: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion

2019 PROSPERO

93. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for Peripheral Vascular Ultrasound and Physiological Testing Part I: Arterial Ultrasound and Physiological Testing

requests that this document be cited as follows: Mohler III ER, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing. J Am Coll Cardiol 2012;60:242–76. The Online Appendix and other supplemental material for this article are available at http://content.onlinejacc.org/cgi/content/full/j.jacc.2012.02.009 (...) uses, as well as from current clinical practice guidelines and results of studies examining the implemen- tation of the original appropriate use criteria (AUC). The 159 indications in this document were developed by a diverse writing group and scored by a separate independent technical panel on a scale of 1 to 9, to designate appropriate use (median 7 to 9), uncertain use (median 4 to 6), and inappropriate use (median 1 to 3). A total of 255 indications (with the inclusion of surveillance

2012 Society for Cardiovascular Angiography and Interventions

94. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update

* Steven R. Bailey, MD, FACC, FSCAI§ Chirojit Mukherjee, MD†† John H. Calhoon, MD‡ Debabrata Mukherjee, MD, FACC* Blase A. Carabello, MD, FACC* Catherine M. Otto, MD, FACC* Milind Y. Desai, MBBS, FACC ¦¶ Carlos E. Ruiz, MD, PhD, FACC, FSCAI§ Fred H. Edwards, MD, FACC† Ralph L. Sacco, MD, MS, FAHA‡‡ Gary S. Francis, MD, FACC# Donnette Smith§§ Timothy J. Gardner, MD, FACC† James D. Thomas, MD, FACC ¦¦ ACCF Task Force Members Robert A. Harrington, MD, FACC, Chair Deepak L. Bhatt, MD, MPH, FACC, Vice Chair (...) ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update 1 © 2012 by the American College of Cardiology Foundation, the American Association for Thoracic Surgery, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. 2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement Developed in collaboration with the American Heart Association, American Society

2012 Society for Cardiovascular Angiography and Interventions

95. CCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update

College of Cardiology Vol. 59, No. 9, 2012 © 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.001 Downloaded From: http://content.onlinejacc.org/ on 09/09/2014Appropriate Use Criteria Task Force Michael J. Wolk, MD, MACC, Chair Steven R. Bailey, MD, FACC, FSCAI, FAHA Pamela S. Douglas, MD, MACC, FAHA Robert C. Hendel, MD, FACC, FAHA, FASNC Christopher M. Kramer, MD, FACC, FAHA James K. Min, MD, FACC Manesh R. Patel, MD (...) , FACC Leslee Shaw, PHD, FACC, FASNC Raymond F. Stainback, MD, FACC, FASE Joseph M. Allen, MA TABLE OF CONTENTS Abstract 858 Preface 859 Introduction 859 Methods 860 Indication Development 860 Scope of Indications 860 Technical Panel Selection 861 Rating Process and Scoring 861 General Assumptions 862 De?nitions 862 Abbreviations 863 Results of Updated Ratings 864 Table A. Focused Update: New or Revised Indications 864 Coronary Revascularization Appropriate Use Criteria (By Indication) 865 Table 1

2012 Society for Cardiovascular Angiography and Interventions

96. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization

ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization doi:10.1016/j.jacc.2012.03.003 published online May 9, 2012; J. Am. Coll. Cardiol. Kirtane, L. Samuel Wann, and R. Parker Ward Robert O. Bonow, Charles E. Chambers, Paul S. Chan, Gregory J. Dehmer, Ajay J. Resonance, Society of Thoracic Surgeons, Manesh R. Patel, Steven R. Bailey, Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic of America, Heart Rhythm (...) 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2012.03.003 by on May 16, 2012 content.onlinejacc.org Downloaded from Appropriate Use Criteria Task Force Michael J. Wolk, MD, MACC, Chair Steven R. Bailey, MD, FACC, FSCAI, FAHA Pamela S. Douglas, MD, MACC, FAHA, FASE Robert C. Hendel, MD, FACC, FAHA, FASNC Christopher M. Kramer, MD, FACC, FAHA James K. Min, MD, FACC Manesh R. Patel, MD, FACC Leslee Shaw, PHD, FACC, FASNC Raymond F. Stainback, MD, FACC, FASE Joseph M. Allen, MA TABLE

2012 Society for Cardiovascular Angiography and Interventions

97. Narrative E-Writing Intervention (NeW-I) for Parents of Children With Chronic Life-Threatening Illness

of more than 3 months since time of study participation so as to ensure successfully completion of all intervention components before child's death. Able to speak, read and write in English, as well as to provide informed consent. Exclusion Criteria: Cannot provide informed consent Suffering from severely high levels of depressive symptoms, anxiety and psychological distress (i. e. score of 19 or higher on Patient Health Questionnaire-9 (PHQ-9) or score of 29 or higher on Kessler Psychological (...) Narrative E-Writing Intervention (NeW-I) for Parents of Children With Chronic Life-Threatening Illness Narrative E-Writing Intervention (NeW-I) for Parents of Children With Chronic Life-Threatening Illness - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

98. E-Support Groups in Multiple Sclerosis

-hr weekly online journaling activities. Behavioral: e-Journaling placebo Online journaling activity. Other Name: e-Journaling Outcome Measures Go to Primary Outcome Measures : Percentage of enrolled participants who completed follow-up questionnaires [ Time Frame: 12 weeks ] Assess feasibility of the program: to retain and obtain completed questionnaires at immediate follow-up from 80% of enrolled participants (meeting the criteria of 75% attendance). Change in UCLA Loneliness Scale total score (...) E-Support Groups in Multiple Sclerosis E-Support Groups in Multiple Sclerosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. E-Support Groups in Multiple Sclerosis (eSupport) The safety and scientific

2018 Clinical Trials

99. Study to Evaluate Constituents in Exhaled Breath and Room Air From Use of E-vapor Products and Conventional Cigarettes

Posted : July 30, 2018 Last Update Posted : December 5, 2018 Sponsor: Juul Labs, Inc. Collaborator: Inflamax Research Incorporated Information provided by (Responsible Party): Juul Labs, Inc. Study Details Study Description Go to Brief Summary: An open-label, single center, three-arm observational study to examine emissions from e-cigarettes versus conventional cigarettes under three environmental settings of typical residential, office and hospitality facilities. Condition or disease Intervention (...) Study to Evaluate Constituents in Exhaled Breath and Room Air From Use of E-vapor Products and Conventional Cigarettes Study to Evaluate Constituents in Exhaled Breath and Room Air From Use of E-vapor Products and Conventional Cigarettes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

100. Evaluation of an E-intervention on MHBC for Chinese Cardiac Patients in Home-based Rehabilitation

(in m) and body weight (in kg) for calculating the BMI, using the equation "BMI=weight/ height square". Other Outcome Measures: Social-demographic information [ Time Frame: At the beginning of intervention (Baseline) ] The items consist of gender, age, marital status, education level, rehabilitation treatment history, and current work status. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk (...) Evaluation of an E-intervention on MHBC for Chinese Cardiac Patients in Home-based Rehabilitation Evaluation of an E-intervention on MHBC for Chinese Cardiac Patients in Home-based Rehabilitation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>